Spero Therapeutics, Inc. (SPRO) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Spero Therapeutics, Inc.

Shattuck Labs, Inc.

Enzo Biochem, Inc.

Avrobio, Inc.

Eliem Therapeutics, Inc.

Nkarta, Inc.

Elicio Therapeutics, Inc.

YS Biopharma Co. Ltd.

Vaccinex, Inc.

HCW Biologics Inc.

Syros Pharmaceuticals, Inc.

Why is Spero Therapeutics, Inc. ?

Poor Management Efficiency with a low ROE of 5.97%

The company has been able to generate a Return on Equity (avg) of 5.97% signifying low profitability per unit of shareholders funds

The company has declared Negative results for the last 3 consecutive quarters

OPERATING CASH FLOW(Y) Lowest at USD -27.67 MM
CASH AND EQV(HY) Lowest at USD 79.81 MM
NET SALES(Q) Lowest at USD 3.05 MM

Risky -

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of 214.99%, its profits have fallen by -1299.7%

Reducing Promoter Confidence

Promoters have decreased their stake in the company by -2.46% over the previous quarter and currently hold 7.41% of the company
Promoters decreasing their stake may signify reduced confidence in the future of the business

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Spero Therapeutics, Inc. for you?

High Risk, High Return

Absolute

Risk Adjusted

Volatility

Spero Therapeutics, Inc.

185.82%

0.26

253.57%

S&P 500

16.12%

0.77

19.29%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

21.55%

EBIT Growth (5y)

6.13%

EBIT to Interest (avg)

-40.38

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.39

Sales to Capital Employed (avg)

1.01

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

29.49%

ROCE (avg)

20.70%

ROE (avg)

5.97%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

5.51

EV to EBIT

-1.76

EV to EBITDA

-1.76

EV to Capital Employed

-4.91

EV to Sales

3.38

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-158.96%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Mildly Bullish

RSI

No Signal

Bearish

Bollinger Bands

Sideways

Bullish

Moving Averages

Mildly Bullish (Daily)

KST

Mildly Bearish

Bullish

Dow Theory

Mildly Bullish

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

11What is working for the Company

RAW MATERIAL COST(Y)

Fallen by 0% (YoY

DEBT-EQUITY RATIO (HY)

Lowest at -170.85 %

PRE-TAX PROFIT(Q)

At USD -6.79 MM has Grown at 61.03%

NET PROFIT(Q)

At USD -6.79 MM has Grown at 60.37%

-9What is not working for the Company

OPERATING CASH FLOW(Y)

Lowest at USD -27.67 MM

CASH AND EQV(HY)

Lowest at USD 79.81 MM

NET SALES(Q)

Lowest at USD 3.05 MM

OPERATING PROFIT MARGIN(Q)

Lowest at -319 %

Here's what is working for Spero Therapeutics, Inc.

Pre-Tax Profit

At USD -6.79 MM has Grown at 61.03%

Year on Year (YoY)

MOJO Watch

Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (USD MM)

Net Profit

At USD -6.79 MM has Grown at 60.37%

Year on Year (YoY)

MOJO Watch

Near term Net Profit trend is positive

Net Profit (USD MM)

Debt-Equity Ratio

Lowest at -170.85 %

in the last five Semi-Annual periods

MOJO Watch

The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Raw Material Cost

Fallen by 0% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Spero Therapeutics, Inc.

Net Sales

At USD 3.05 MM has Fallen at -61.02%

Year on Year (YoY)

MOJO Watch

Near term sales trend is extremely negative

Net Sales (USD MM)

Operating Cash Flow

Lowest at USD -27.67 MM and Fallen

In each year in the last three years

MOJO Watch

The company's cash revenues from business operations are falling

Operating Cash Flows (USD MM)

Net Sales

Lowest at USD 3.05 MM

in the last five periods

MOJO Watch

Near term sales trend is negative

Net Sales (USD MM)

Operating Profit Margin

Lowest at -319 %

in the last five periods

MOJO Watch

Company's profit margin has deteriorated

Operating Profit to Sales

Cash and Eqv

Lowest at USD 79.81 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is deteriorating

Cash and Cash Equivalents